CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
Provided By GlobeNewswire
Last update: Mar 13, 2025
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.
Read more at globenewswire.com0.8901
-0.22 (-19.81%)
Find more stocks in the Stock Screener
CERO Latest News and Analysis
13 hours ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
15 hours ago - ChartmillTop stock movements in today's session.Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.
2 days ago - ChartmillThursday's session: top gainers and losersHere are the top movers in Thursday's session, showcasing the stocks with significant price changes.
2 days ago - ChartmillKeep an eye on the top gainers and losers in Thursday's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
2 days ago - ChartmillWhich stocks are gapping on Thursday?In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
